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Edited by Robert BaroukiAbstract Hypoxia inducible factor-1alpha (HIF1a) plays a key
role in the regulation of genes controlling oxygen supply, glucose
metabolism and angiogenesis. Its expression in tumors appears
to confer an adaptive advantage to their hypoxic microenviron-
ment. We have evaluated the eﬀect of the immunophilin ligands
FK506 and cyclosporin A on HIF1a levels in diﬀerent tumor cell
lines. Our results indicate that both drugs are potent suppressors
of HIF1a expression by accelerating the proteasomal degrada-
tion of the protein. Unexpectedly, the suppressive eﬀect of these
compounds was found to be independent of the presence of von
Hippel Lindau factor and the degree of hydroxylation of the
HIF1a protein. Moreover, HIF1a degradation induced by these
compounds did not required ubiquitination, as it was also induced
in E1 ligase-incompetent cells.
 2006 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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The expression of the hypoxia-inducible factor HIF-1 has
been associated with an aggressive phenotype in several malig-
nant tumors [1]. This is likely associated with its ability to in-
duce the expression of pro-angiogenic and pro-glycolytic
genes that enhance tumor survival in an adverse microenviron-
ment [2]. Furthermore, expression of HIF-1 appears to play an
important role in regulating radiosensitivity, thus making HIF-
1 a promising target for primary tumor therapy and radiosen-
sitisation [3]. In order to develop targeted anti-HIF therapies
it is important to understand the mechanisms that regulate
HIF-1 expression. The HIF-1 complex is formed by two types
of sub-units, the HIF1b which is constitutively expressed and
the HIF1a, whose expression is dependent on tissue oxygena-
tion. Under normal oxygen conditions, the HIF1a sub-units
are constitutively translated but rapidly degraded by the ubiq-
uitin–proteasome system in a process that requires the presence
of the von Hippel Lindau (VHL) protein that acts as an ubiq-Abbreviations: HIF1a, hypoxia inducible factor1; VHL, von Hippel
Lindau; CsA, cyclosporin A; Cyp, cyclophilin; FKBP, FK506 binding
protein
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depends on the hydroxylation of prolyl residues in the oxygen
degradation domain (ODD) on the HIFa proteins. This
hydroxylation process is dependent on speciﬁc iron-containing
hydroxylase enzymes (PHDs) that utilize oxygen, iron and oxo-
glutarate as co-factors [6,7]. However, the determinants of the
HIF1a proteins half-life appears to be much more complex
and involves the interaction with several chaperone complexes
that modulate the protein conformation, maturation and its
translocation to the nuclei. Furthermore, other post-transla-
tional modiﬁcation such as phosphorylation and acetylation
may inﬂuence HIF survival [8,9].
Although protein folding was thought to be a spontaneous
process determined by the linear amino acid sequence, it is
now clear that to attain the proper conformation most protein
need the assistance of chaperone complexes. Of special interest
for HIF-1 complex formation is the interaction of the HIF1a
subunit with the HSP90 complex. Typically, HSP90 associates
as a dimmer with its client proteins at later stages of the folding
process following the initial client interaction with the HSP70
chaperone complex. Thus, inhibition of HSP90 function by
drugs that aﬀect the ATP-binding site at the N-terminal of
HSP90, like geldanamycin and its relatives, results in prema-
ture degradation of HIF1a and inhibition of its function
[10,11]. Furthermore, it was recently shown that hyperacetyla-
tion of HSP90 by the use of deacetylase inhibitors resulted in a
VHL and ubiquitin-independent degradation of HIF1a [9].
The HSP90 chaperone complex works in association with sev-
eral co-chaperone proteins that are important for its function
[12]. Among these co-chaperone proteins are the members of
the families of FK506 and cyclosporin A (CsA) binding immu-
nophilins [13,14]. Of great interest, these immunophilins have
peptidyl prolyl cis/trans (PPIase) activity that is inhibited by
the binding of their cognate binder, i.e. FK506 and CsA.
The immunosuppressive drugs FK506 and CsA are widely
used for the prevention of transplant rejection and as general
inhibitors of T cell function because they are potent inhibitors
of the Ca2+/calmodulin dependent Ser/Thr phosphatase calci-
neurin, a critical component of antigen-receptor signaling
through nuclear factor of T cells (NFAT). The drugs alone
do not inhibit calcineurin by themselves, but require the bind-
ing to their respective immunophilins (Cyp A and FKFB12), in
a gain-of-function mechanism [13].
Immunosuppressive agents like CsA and Rapamycin have
been reported to inhibit angiogenesis by inhibiting HIF-medi-
ated VEGF expression [15,16] and an earlier report had indi-
cated that CsA inhibited HIF by enhancing its hydroxylationblished by Elsevier B.V. All rights reserved.
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and CsA inhibit HIF1a expression in several tumor cell lines
by a process that is independent of VHL and HIF-hydroxyl-
ation and appears to be independent of the inhibition of calci-
neurin.2. Materials and methods
2.1. Cell culture
Cell lines HT1080 and HeLa were from ATCC (Manassas, VA). Re-
nal cell carcinoma RCC4 VHL (/) and VHL (+/+) were generously
provided by Dr. Ratcliﬀe (Oxford University, England), and Ts20 cells
were from Dr. Ozer (Rutgers Univ, NJ). Cells except Ts20 were cul-
tured at 37 C, 5% CO2 in recommended media supplemented with
10% FBS. Ts20 cells were cultured at 35 C or 39 C according to
the experimental requirement as described previously [9]. Hypoxia
(1% O2/5% CO2) was conducted in an oxygen station (In VIVO2,
Ruskin Tech).
2.2. Chemicals and reagents
Common chemicals, solvents and general reagents including cyclo-
sporin A, FK506, desferroxamine, MG132 were from Sigma (St.
Louis, MO). Dimethyloxallylglycine (DMOG) was from Cayman
Chemical Co. (Ann Arbor, MI) and calcineurin autoinhibitory peptide
was from Calbiochem (San Diego, CA).
2.3. Antibodies and immunoblots
Antibodies were from the following providers: monoclonal anti-
hHIF-1a from BD-Biosciences (San Diego, CA) and anti-mHIF-1a
from R&D Systems (MS); monoclonal anti-a-tubulin was from
Santa-Cruz (Santa Cruz, CA); polyclonal anti-hydroxylated HIF-1a
was a generous gift from Dr. Ratcliﬀe.
The preparation of cell extracts for western blots was described pre-
viously; brieﬂy cells were homogenized in 8 M urea buﬀer (8 M urea in
10 mM Tris, pH 6.8, 1% SDS, 5 mM DTT in the presence of a 1· pro-
tein inhibitor mix) with a portable Ultra-Turrax homogenator. Protein
electrophoresis used 60 lg of total cell extracts for each sample andFig. 1. Eﬀect of cyclosporin A (CsA) and FK506 on HIF1a and gene express
of FK506 (A) or CsA (B) at 5 or 10 lM concentrations in the presence or a
analyzed by Western blots against HIF1a or tubulin. (C) RNA expression u
Glucose transporter 1(Glut1), carbonic anhydrase 9(CA9) and B-actin in tota
CsA. (D) Normoxic HT1080 cells were exposed to MG132 in the presence o
HIF1a was measured over time.was resolved by SDS–PAGE, transferred to PVDF membrane, immu-
noblotted with primary and HRP conjugated secondary antibodies.
An ECL-plus kit (Amersham) was used to detect the signal.
2.4. RNA isolation and RT-PCR
Total RNA was isolated from cells using a kit (RNeasy) from
Qiagen (Valencia, CA) based on manufacture’s instruction. Following
digestion with RNAse-free DNase, reverse transcription was per-
formed using the RT-kit from La Roche. Semi-quantitative PCR
was optimized for each individual target. Primers utilized were as
described previously [9].
2.5. Plasmids and transfections
Full length HIF-1a, HIF-1aD392-575 (originally provided by Dr.
Semenza) and HIF-1a P402A, P564G (originally provided by Dr.
Ratcliﬀe) were cloned into pShooter vector containing a nuclear local-
ization signal and a Myc-tag (InVitrogen) by PCR- based strategies
and conﬁrmed by DNA sequencing. Transfections were performed
as previously described using Lipofectamine 2000 (InVitrogen).3. Results
3.1. Inhibition of HIF-1a protein and HIF-1 regulated gene
expression by immunosuppressors FK506 and CsA
The eﬀect of CsA and FK506 on HIF 1a expression was
tested in HT1080 cells exposed to hypoxia (1% O2) for 6 h.
As shown in Fig. 1A and B, both drugs produce a dose-depen-
dent inhibition in HIF1a protein. The addition of the protea-
some inhibitor MG132 completely reversed the eﬀects of the
drugs suggesting that they acted by enhancing the proteasomal
degradation of the protein. Similar results were observed when
using HeLa and renal carcinoma cell lines (not shown). The
drugs did not aﬀect HIF1a mRNA levels but signiﬁcantly
inhibited the response of HIF-1 regulated genes like VEGF,
Glut 1 and CA9 (Fig. 1C). To conﬁrm that both drugs didion. HT1080 cells were exposed to hypoxia (Hx) for 6 h in the presence
bsence of 10 lM of MG132 (proteasomal inhibitor). Cell lysates were
sing PCR against HIF-1, vascular endothelial growth factor (VEGF),
l RNA from normoxic (21% O2) or hypoxic (1% O2) cells treated with
r absence of CsA (10 lM) or FK506 (10 lM) and the accumulation of
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mulation of HIF1a protein in normoxic HT1080 cells treated
with MG132 in the presence or absence of FK506 and CsA.
As shown in Fig. 1D, the accumulation of HIF1a protein
was not aﬀected by the presence of either FK506 or CsA at
concentrations that inhibited the HIF response to hypoxia.
3.2. HIF1a degradation induced by immunosuppressive drugs is
not VHL- nor ODD-dependent
The physiological degradation of HIF1a involves the oxy-
gen-dependent hydroxylation of prolyl-residues 402 and 564
and the subsequent interaction with the VHL protein that acts
as an ubiquitin ligase (E3). In a previous report D’Angelo and
co-workers reported that treatment with CsA promotes the
hydroxylation of Pro-564, thus enhancing its interaction with
VHL and promoting its degradation [17]. To test the roles of
HIF-hydroxylation and VHL on the degradation of HIF1a in-
duced by CsA and FK506 we utilized the VHL deﬁcient RCC4
cells (VHL /). Because of the lack of VHL, these cells ex-
press constitutively high levels of HIF1a in normoxic condi-
tions. Fig. 2A shows that CsA inhibited HIF1a expression in
RCC4 VHL (/) in a similar dose-dependent way as in
VHL (+/+), the eﬀect was also reversed by MG132. The time
course eﬀect of CsA in VHL (/) cells is shown in Fig. 2B.
These results suggested that these drugs do not increase prolyl
hydroxylase activities but acted through a VHL-independent
pathway. Further conﬁrmation of the independence of hydro-
xylation was obtained by measuring the degree of Pro-564
hydroxylation using a speciﬁc antibody that recognizes only
the hydroxylated form of HIF1a [7]. As shown in Fig. 2C, nei-
ther CsA nor FK506 enhanced the hydroxylation of HIF1aFig. 2. CsA-induced degradation of HIF1a is VHL and ODD-independent.
to increasing concentrations of CsA for 6 h in the absence or presence of MG1
CsA inhibition of HIF1a expression in RCC4 VHL (/) cells. (C) Normoxic
absence of CsA or FK506 and cell lysates analyzed using anti-HIF1a antibo
(HIF-OH). (D) Plasmids containing sequences for wild type HIF1a (HIF), m
ODD domain (HIFDODD) were transfected into HT1080 cells and exposed(HIF-OH) in hypoxic cells treated with MG132 and CsA or
FK506 at doses that were eﬀective in suppressing HIF1a
expression. Moreover, both drugs suppressed HIF1a expres-
sion in cells treated with DMOG (dimethyloxalylglicine) or
iron chelators, which are strong inhibitors of prolylhydroxy-
lase activity (not shown). To further examine the role of the
HIF-ODD on the eﬀects of these drugs on HIF1a survival
we tested the eﬀect of FK506 and CsA on HIF1a mutants con-
taining either proline substitutions at positions 402 and 564
(A402P and G564P) or a deletion of the ODD between amino
acids 392 and 575 (D392–575). Results shown in Fig. 2D indi-
cate that the absence of hydroxylation sites or the complete
deletion of the ODD did not aﬀect the suppressive eﬀects of
these drugs on HIF1a expression, which was similar as the ob-
tained with the transfection of a wild type HIF1a.
3.3. Enhanced degradation of HIF1a by immunosuppressive
drugs is ubiquitin independent
Since the above results indicated that HIF hydroxylation
and VHL were not involved in the eﬀects of FK506 and
CsA, we investigated whether ubiquitination of the protein
was necessary for the eﬀect of these drugs. To test this eﬀect
we utilized Ts20 cells that express a temperature sensitive mu-
tant of the E1 enzyme and express HIF1a when the tempera-
ture is increased to 39 C. Results shown in Fig. 3A indicate
that treatment with CsA or FK506 for 6 hours produced an
almost complete suppression of HIF1a in Ts20 cells incubated
at 39 C. Most interestingly, this eﬀect was completely reversed
by the simultaneous use of the proteasome inhibitor MG132,
suggesting that these drugs induce an ubiquitin-independent,
proteasomal-dependent degradation of HIF1a.(A) VHL deﬁcient (/) and VHL competent (+/+) cells were exposed
32. HIF1a and tubulin were measured by Westerns. (B) Time course of
and hypoxic HT1080 cells were exposed to MG132 in the presence and
dies (HIF) or antibodies speciﬁc for the hydroxylated form of HIF1a
utations in prolyl residues 402 and 564 (HIF-mut), and a deletion in the
to hypoxia in the presence and absence of 5 lM of CsA.
Fig. 3. Degradation of HIF1a induced by CsA is ubiquitin-indepen-
dent and does not involve the inhibition of calcineurin. (A) Ts20 cells,
containing the temperature sensitive form of E1, were exposed to 39 C
for 18 h and then treated with CsA (10 lM) in the presence or absence
of MG132 for indicated time period, HIF1a and tubulin were detected
by Western blots. (B) HT1080 cells were exposed to hypoxia for 6 h in
the presence or absence of CsA (5 lM) or FK506 (5 lM) or calcineurin
inhibitor peptide (Inh) at 10 or 50 lM concentrations, HIF1a and
tubulin were detected by Western blots.
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calcineurin
The immunosuppressive eﬀects of CsA and FK506 are med-
iated by the inhibition of calcineurin, a Ser/Tre phosphatase
involved in antigen signaling in T cells. This eﬀect is mediated
by a gain of function of the complexes between the drugs and
their corresponding immunophilins, cyclophilin 18 and
FKBP12. To test whether the eﬀect of these drugs on HIF1a
expression was mediated through calcineurin inhibition we uti-
lized a cell permeable calcineurin autoinhibitory peptide [18].
As shown in Fig. 3B, treatment of HT1080 cells with high
doses of the inhibitory peptide had no eﬀect on HIF1a
response to hypoxia. These results suggest that calcineurin
inhibition is not involved in the action of CsA or FK506 on
HIF1a expression.4. Discussion
The regulation of HIF1a levels results from the dynamic
equilibrium between its synthesis and its degradation by the
proteasome system. In conditions where oxygen is readily
available, HIF1a is rapidly degraded by a process that involves
its hydroxylation and subsequent ubiquitilation and protea-
somal degradation [reviewed in [19]]. The VHL protein is an
essential component of this pathway by acting as the speciﬁc
E3-ligase and its absence results in the constitutive expression
of HIF1a protein and its target genes [4]. As such, VHL deﬁ-
cient tumors are characterized by the high expression of angio-
genic factors and glycolytic enzymes. As tumors are usually in
a hypoxic microenvironment, the expression of HIF1a appearsto facilitate tumor growth and spread. As such, HIF1a has
been considered a potential target for direct tumor treatment
or as an adjuvant to chemo or radiotherapy [3].
Immunosuppressive agents like FK506, CsA and Rapamy-
cin have been used for long to prevent graft rejection or for
the therapy of autoimmune diseases. Of interest, these drugs
have also shown eﬃcacy as antiangiogenic and potential anti-
tumor agents [15,16]. Our results clearly indicate that both
CsA and FK506 are potent inhibitors of HIF1a expression
in various cell lines. Moreover, this inhibitory activity extends
to HIF-regulated genes such as VEGF, Glut-1 and CAIX. In
an earlier report, D’Angelo and co-workers had demonstrated
that CsA inhibited the expression of HIF1a in response to
hypoxia at doses similar to the ones used here [17]. They
suggested that CsA acted by stimulating the activity of
prolyl-hydroxylase enzymes and thereby promoting HIF-
hydroxylation and its subsequent association with VHL. How-
ever, our results indicate that the eﬀect of CsA and FK506 was
independent of hydroxylation since mutations at Pro-402 and
Pro-564, the sites of HIF-hydroxylation, or a deletion of the
ODD, did not aﬀect the inhibitory eﬀects of these drugs. More-
over, CsA and FK506 were equally inhibitory in VHL-compe-
tent (VHL +/+) as well as in VHL-deﬁcient cells (VHL /).
The ﬁnding that proteasomal inhibitors completely reversed
the eﬀect of CsA and FK506 indicate that they act primarily by
accelerating the degradation of HIF1a. Interestingly, this pro-
teasomal degradation was independent of VHL, the normal
HIF1a E3-ligase. Furthermore, the drug-induced degradation
of HIF1a was independent of ubiquitination, as it occurred
both in E1 deﬁcient and E1 competent cells. Although the
mechanisms by which these drugs induce a VHL- and ubiqui-
tin-independent degradation of HIF1a are not completely
clear, they resemble the recently described eﬀect of deacetyl-
ase-inhibitors on HIF1a survival [9]. In that last case, the
inhibitors act through the inhibition of the HSP70-HSP90 axis.
As immunosuppressive agents, FK506 and CsA act as inhibi-
tors of the Ca2+ regulated phosphatase calcineurin. This eﬀect
is mediated by a gain of function following their association
with their cognate immunophilins FKBP12 and Cyp18
[13,16]. However, our ﬁnding that a speciﬁc cell permeable cal-
cineurin autoinhibitory peptide had no eﬀect on HIF1a expres-
sion makes this mechanism unlikely. FKFB12 and CyA are
part of a large family of proteins known as immunophilins
which characteristically possess peptidylprolyl isomerase activ-
ity (PPIase’s) [13,14], In addition to their PPIase activity, these
immunophilins appear to also have chaperone function and
some of their members participate in steroid receptor complex
maturation [20]. Moreover, they appear to be active in the pro-
cess of cytoplasmic/nuclear transfer as they interact with
dynein to facilitate the retrograde movement of proteins from
the cytoplasm to the nuclei along microtubular tracks [12].
Although our results clearly indicate that CsA and FK506
are inhibitors of HIF1a expression, it is yet unclear whether
they act as inhibitors of the PPIase or co-chaperone activities
of the immunophilins. Resolution of these issues will be impor-
tant for a better understanding of the physiological process of
HIF1a maturation and for the possible development of more
speciﬁc HIF1a inhibitors.Acknowledgements: We thank Drs. P. Ratcliﬀe and G. Semenza for
providing us with critical reagents. This work was partially supported
by CA089212 to J.C.
6186 X. Kong et al. / FEBS Letters 580 (2006) 6182–6186References
[1] Semenza, G.L. (2003) Targeting HIF-1 for cancer therapy. Nat.
Rev. Cancer 3, 721–732.
[2] Esteban, M.A. and Maxwell, P.H. (2005) HIF, a missing link
between metabolism and cancer. Nat. Med. 11, 1047–1048.
[3] Moeller, B.J. and Dewhirst, M.W. (2006) HIF-1 and tumour
radiosensitivity. Br. J. Cancer 95, 1–5.
[4] Kaelin Jr., W.G. (2005) The von Hippel-Lindau protein, HIF
hydroxylation, and oxygen sensing. Biochem. Biophys. Res.
Commun. 338, 627–638.
[5] Schoﬁeld, C.J. and Ratcliﬀe, P.J. (2005) Signalling hypoxia by
HIF hydroxylases. Biochem. Biophys. Res. Commun. 338, 617–
626.
[6] Metzen, E. and Ratcliﬀe, P.J. (2004) HIF hydroxylation and
cellular oxygen sensing. Biol. Chem. 385, 223–230.
[7] Knowles, H.J., Mole, D.R., Ratcliﬀe, P.J. and Harris, A.L. (2006)
Normoxic stabilization of hypoxia-inducible factor-1alpha by
modulation of the labile iron pool in diﬀerentiating U937
macrophages: eﬀect of natural resistance-associated macrophage
protein 1. Cancer Res. 66, 2600–2607.
[8] Bramihi-Horn, C., Mazure, N. and Pouyssegur, J. (2005) Signal-
ling via the hypoxia-inducible factor-1alpha requires multiple
posttranslational modiﬁcations. Cell. Signal. 17, 1–9.
[9] Kong, X., Lin, Z., Liang, D., Fath, D., Sang, N. and Caro, J.
(2006) Histone deacetylase inhibitors induce VHL and ubiquitin-
independent proteasomal degradation of hypoxia-inducible factor
1alpha. Mol. Cell. Biol. 26, 2019–2028.
[10] Katschinski, D.M., Le, L., Heinrich, D., Wagner, K.F., Schindler,
S.G. and Wenger, R.H. (2002) Heat induction of the unphos-
phorylated form of hypoxia-inducible factor-1alpha is dependent
on heat shock protein-90 activity. J. Biol. Chem. 277, 9262–9267.
[11] Issacs, J.S., Jung, Y.J., Mimnaugh, E.G., Martinez, A., Cuttitta,
F. and Neckers, L.M. (2002) Hsp90 regulates a von HippelLindau-independent hypoxia-inducible factor-1 alpha-degrada-
tive pathway. J. Biol. Chem. 277, 29936–29944.
[12] Pratt, W.B., Galigniana, M.D., Harrell, J.M. and DeFranco, D.B.
(2004) Role of hsp90 and the hsp90-binding immunophilins in
signalling protein movement. Cell. Signal. 16, 857–872.
[13] Gothel, S.F. and Marahiel, M.A. (1999) Peptidyl-prolyl cis–trans
isomerases, a superfamily of ubiquitous folding catalysts. Cell.
Mol. Life Sci. 55, 423–436.
[14] Fisher, G. and Aumuller, T. (2003) Regulation of peptide bond
cis/trans isomerization by enzyme catalysis and its implication in
physiological processes. Rev. Physiol. Biochem. Pharmacol. 148,
105–150.
[15] Cho, M.L., Cho, C.S., Min, S.Y., Kim, S.H., Lee, S.S., Kim,
W.U., Min, D.J., Min, J.K., Youn, J., Hwang, S.Y., Park, S.H.
and Kim, H.Y. (2002) Cyclosporin inhibition of vascular endo-
thelial growth factor production in rheumatoid synovial ﬁbro-
blasts. Arthritis Rheum. 46, 1202–1209.
[16] Del Bufalo, D., Ciuﬀreda, L., Trisciuoglio, D., Desideri, M.,
Cognetti, F., Zupi, G. and Milella, M. (2006) Antiangiogenic
potential of the Mammalian target of rapamycin inhibitor
temsirolimus. Cancer Res. 66, 5549–5554.
[17] D’Angelo, G., Duplan, E., Vigne, P. and Frelin, C. (2003)
Cyclosporin A prevents the hypoxic adaptation by activating
hypoxia-inducible factor-1alpha Pro-564 hydroxylation. J. Biol.
Chem. 278, 15406–15411.
[18] Terada, H., Matsushita, M., Lu, Y.F., Shirai, T., Li, S.T.,
Tomizawa, K., Moriwaki, A., Nishio, S., Date, I., Ohmoto, T.
and Matsui, H. (2003) Inhibition of excitatory neuronal cell death
by cell-permeable calcineurin autoinhibitory peptide. J. Neuro-
chem. 87, 1145–1151.
[19] Maxwell, P.H. (2005) The HIF pathway in cancer. Semin. Cell
Dev. Biol. 16, 523–530.
[20] Picard, D. (2006) Chaperoning steroid hormone action. Trends
Endocrinol. Metab. 17, 229–235.
